2014
DOI: 10.1016/j.bmc.2014.04.019
|View full text |Cite
|
Sign up to set email alerts
|

Biased and unbiased strategies to identify biologically active small molecules

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
16
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(16 citation statements)
references
References 115 publications
0
16
0
Order By: Relevance
“…Peptide inhibitors and small molecules are extensive ly used in medicine [168,169]. These peptides usually consist of 5 40 a.a.…”
Section: Iress Of Viral Rnas As a Pharmaceutical Targetmentioning
confidence: 99%
See 1 more Smart Citation
“…Peptide inhibitors and small molecules are extensive ly used in medicine [168,169]. These peptides usually consist of 5 40 a.a.…”
Section: Iress Of Viral Rnas As a Pharmaceutical Targetmentioning
confidence: 99%
“…Currently, small molecules are preferred drugs [169]. There are new approaches directed toward generation of libraries of small molecules with desired properties [169].…”
Section: Iress Of Viral Rnas As a Pharmaceutical Targetmentioning
confidence: 99%
“…If the number of drugs reaching the clinic is the yardstick, it must be concluded that this approach has not worked. This is considered to be largely due to the limited structural diversity inherent in conventional combinatorial libraries, and indeed has prompted renewed interest in the development of drugs from natural sources [93][94][95]. However, natural product drug discovery has its limitations too, including difficulties with the resupply of raw materials, difficulties with the repeated isolation of known compounds, and difficulties with synthesizing natural compounds of interest [94].…”
Section: Drug Discovery Strategiesmentioning
confidence: 99%
“…This is considered to be largely due to the limited structural diversity inherent in conventional combinatorial libraries, and indeed has prompted renewed interest in the development of drugs from natural sources [93][94][95]. However, natural product drug discovery has its limitations too, including difficulties with the resupply of raw materials, difficulties with the repeated isolation of known compounds, and difficulties with synthesizing natural compounds of interest [94]. More recently, hybrid approaches have been developed whereby combinatorial libraries incorporate the broader chemical diversity of natural products [96,97].…”
Section: Drug Discovery Strategiesmentioning
confidence: 99%
“…We preferred a diversity-oriented synthesis strategy with the aim of generating both skeletal and appendage diversity 15 and were attracted to the so-called "build couple pair" approach ( Figure 1). …”
mentioning
confidence: 99%